Alyssa C. Hill

Alyssa completed a Ph.D. in 2017. Her doctoral work focused on the biophysical properties of RNA and was supported by a Graduate Research Fellowship from the U.S. National Science Foundation. From 2017 to 2023, Alyssa carried out postdoctoral work in pharmaceutical chemistry at Eidgenössische Technische Hochschule (ETH) Zürich, Switzerland. Her projects tackled delivery challenges for nucleic acid therapeutics, particularly small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and ASO conjugates, with support from the Novartis Research Foundation, Swiss National Science Foundation, and Roche Innovation Center Copenhagen. Alyssa leads an in vitro ASO screening workstream within the CureHeart consortium.

Publications:        

Synthesis, biophysical and biological evaluation of splice-switching oligonucleotides with multiple LNA-phosphothiotriester backbones. Dhara D. et al. (2024). Journal of the American Chemical Society

Peptide conjugates of a 2'-O-methoxyethyl phosphorothioate splice-switching oligonucleotide show increased entrapment in endosomes. Hill AC. et al. (2023). ACS Omega

The MOE modification of RNA: Origins and widescale impact on the oligonucleotide therapeutics field. Hill AC. et al. (2023). Helvetica Chimica Acta

Chemically synthesized, self-assembling small interfering RNA-prohead RNA molecules trigger Dicer-independent gene silencing. Hill AC. et al. (2022) Chemistry – A European Journal

Innovative developments and emerging technologies in RNA therapeutics. Halloy F. et al. (2022). RNA Biology